Year: 2024

SANTA CLARA, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) — Agora, Inc. (NASDAQ: API), a pioneer and leader in real-time engagement technology, will release its financial results for the third quarter ended September 30, 2024 after the close of U.S. markets on November 25, 2024. Agora, Inc. will host a conference call to discuss the financial results at 5 p.m. Pacific Time / 8 p.m. Eastern Time on the same day. Details for the conference call are as follows: Event title: Agora, Inc. 3Q 2024 Financial Results The call will be available at https://edge.media-server.com/mmc/p/wie28zvr Investors who want to hear the call should log on at least 15 minutes prior to the broadcast. Participants may register for the call with the link below. https://register.vevent.com/register/BIf58a0b6f500c4362b1a8c64f9fa4cea8 Please visit Agora, Inc.’s investor...

Orphan Drug Designation has been granted lately by US FDA RAMAT GAN, Israel, Nov. 11, 2024 (GLOBE NEWSWIRE) — Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announces the dosing of the first patient in the Phase IIa  clinical trial in patients with advanced pancreatic adenocarcinoma (NCT06387342).  “We are excited to have the first patient enrolled and hope that we will be able to demonstrate the safety and efficacy of Namodenoson in the pancreatic cancer patient population. This trial provides us the opportunity to explore our innovative treatment approach for patients who are facing significant gaps in effective treatment options,” stated Dr. Michael Silverman, Can-Fite’s Medical...

Planegg/Martinsried, November 11, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies for the treatment of cancer, presented latest updates on its End-to-End (E2E) Platform technology – the UniTope and TraCR technology, a universal detection system for tagging and tracking recombinant TCRs (rTCRs), at the Protein & Antibody Engineering Summit (PEGS) in Barcelona from November 5-7, 2024, and the Society of Immunotherapy of Cancer (SITC) 2024 conference in Houston, TX, USA from November 6-10, 2024. The presentation ”Seamless Integration of a Universal Epitope into Recombinant TCRs for Tagging and Tracking of TCR-T Cells Expressing 3S TCRs” and the poster “UniTope & TraCR – A universal tagging...

GUANGZHOU, China, Nov. 11, 2024 (GLOBE NEWSWIRE) — EHang Holdings Limited (“EHang” or the “Company”) (Nasdaq: EH), the world’s leading Urban Air Mobility (“UAM”) technology platform company, today announced a long-term strategic partnership and technology development cooperation with Zhuhai Enpower Electric Co., Ltd. (“Enpower”, SZ300681), a pioneer in new energy vehicle (“NEV”) power systems, to co-develop high-performance electric motors and motor controllers for EHang’s suite of electric vertical take-off and landing (“eVTOL”) aircraft.(Photo: Signing Ceremony of Strategic Partnership and Technology Development Cooperation Agreements between EHang and Enpower) The collaboration will focus on creating customized electric motor drive systems that meet the unique specifications of EHang’s diverse eVTOL products and the rigorous...

        Company Announcement No 54/2024Peberlyk 46200 AabenraaDenmark Tel +45 74 37 37 37Fax +45 74 37 35 36 Sydbank A/SCVR No DK 12626509, Aabenraasydbank.dk11 November 2024  Dear Sirs Major shareholder announcement – Sydbank A/S Referring to section 31 of the Danish Capital Markets Act this is to announce that as at 8 November 2024 Sydbank A/S has through direct and indirect holdings at its disposal 2,732,283 shares in Sydbank A/S, equal to 5.00% of the total number of shares in Sydbank A/S. The Bank’s holding of own shares is predominantly attributable to the Bank’s share buyback programme of DKK 1,200 million. The share buyback programme was initiated on 28 February 2024 and will be completed on 31 January 2025 at the latest. The share buyback programme is described in detail in Company Announcement 03/2024. Yours sincerely Sydbank...

Company announcement no. 50 2024  Group CommunicationsBernstorffsgade 40DK-1577 København VTel. +45 45 14 00 00 11 November 2024Danske Bank share buy-back programme: Transactions in week 45 On 2 February 2024, Danske Bank A/S announced a share buy-back programme for a total of DKK 5.5 billion, with a maximum of 70 million shares, in the period from 5 February 2024 to 31 January 2025, at the latest, as described in company announcement no. 2 2024. The programme is being carried out under Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 April 2014 and the Commission’s delegated regulation (EU) 2016/1052 of 8 March 2016, also referred to as the Safe Harbour Rules. The following transactions were made under the share buy-back programme in week 45:  Number of shares VWAP DKK Gross valueDKKAccumulated,...

In week 45, Heimar hf. (“Heimar”) purchased 4,000,000 own shares at a total purchase price of 134,600,000 ISK, as follows:Date Time Shares Purchased Transaction Price (Rate)  Purchase Price (ISK)04.11.2024   09:42   1,000,000 33.3 33,300,00005.11.2024   09:38   1,000,000 33.3 33,300,00007.11.2024   09:32   1,000,000 34 34,000,00008.11.2024   10:24   1,000,000 34 34,000,000Total   4,000,000   134,600,000The transactions are in accordance with Heimar’s buyback program, which was announced on October 16, 2024. According to the program, the buybacks will amount to a maximum of ISK 500,000,000 in total, and the program will remain in effect until that limit is reached, but no later than the company’s 2025 Annual General Meeting. Heimar owned 23,312,500 shares prior to the above transaction, and following these purchases,...

Nasdaq CopenhagenEuronext DublinLondon Stock ExchangeOther stakeholders Date        11 November 2024 Share buyback programme – week 45 The share buyback programme runs in the period 1 February 2024 up to and including 27 January 2025, see company announcement of 31 January 2024. Part I of the programme, for DKK 750 million, was completed on 27 June 2024, see company announcement of 28 June 2024. Part II of the programme, for DKK 775 million and a maximum of 1,550,000 shares, is for execution in the period 28 June 2024 – 27 January 2025. The programme is implemented in compliance with EU Commission Regulation No. 596/2014 of 16 April 2014 and EU Commission Delegated Regulation No. 2016/1052 of 8 March 2016, which together constitute the “Safe Harbour” rules. The following transactions have been made under the programme:Date Number...